CON
Concentra Group Holdings Parent, Inc.
CON has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CON overall, supported by stronger valuation and stronger fundamentals.
CON Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Under pressure |
CON's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CON PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $26.73 | -38% |
| Fair | 18x | $30.20 | -30% |
| Expensive | 22x | $37.55 | -13% |
| Forward | 23x | $42.99 | — |
| Current | 25x | $42.99 | — |
Historical ranges are pointers, not guarantees.
CON's PE is in its expensive range at 25x. If earnings grow as analysts expect, today's price would be 23x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CON in the historical PE scenario, which offers more potential upside but is not a forecast.
CON Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CON, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CON Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.87 | +11% |
| Q3 2026 | $1.69 | +40% |
| Q2 2026 | $1.55 | +29% |
| Q1 2026 | $1.39 | +3% |
| Q4 2025 | $1.30 | -9.7% |
| Q3 2025 | $1.21 | +13% |
| Q2 2025 | $1.20 | +7.1% |
| Q1 2025 | $1.35 | +30% |
| Q4 2024 | $1.44 | +41% |
CON has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $622.1M | +8.6% |
| Q2 2026 | $606M | +10% |
| Q1 2026 | $569.6M | +14% |
| Q4 2025 | $539.1M | +16% |
| Q3 2025 | $572.8M | +17% |
| Q2 2025 | $550.8M | +15% |
| Q1 2025 | $500.8M | +7.1% |
| Q4 2024 | $465M | +5.5% |
CON's revenue has grown year over year every quarter since early 2024: $622M last quarter, up 8.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +2 points |
| Q2 2026 | 19% | +2.7 points |
| Q1 2026 | 17% | +0.8 points |
| Q4 2025 | 13% | +0.2 points |
| Q3 2025 | 16% | -1.1 points |
| Q2 2025 | 16% | -1.3 points |
| Q1 2025 | 16% | -0.1 points |
| Q4 2024 | 13% | +1.6 points |
CON has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CON on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $29.4M | -25% |
| Q2 2026 | $119.5M | +89% |
| Q1 2026 | $9.9M | +$14M |
| Q4 2025 | $98.5M | +28% |
| Q3 2025 | $39.4M | -22% |
| Q1 2025 | -$4M | -115% |
| Q4 2024 | $77M | +47% |
| Q3 2024 | $50.8M | +18% |
CON generated $257M in free cash flow over the past year, up 47% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
CON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -683K shares |
| 1 year | -0.8% | -1.1M shares |
| 3 years | +0.4% | +510K shares |
CON has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $34.7M |
| Q2 2026 | $11M |
| Q1 2026 | $15M |
| Q4 2024 | $15.4M |
| Q1 2024 | — |
| Q4 2023 | $5.3M |
| Q3 2023 | — |
| Q2 2023 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CON Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.5x | Elevated |
| Q4 2025 | 3.7x | Elevated |
| Q3 2025 | 4.0x | Elevated |
| Q2 2025 | 4.2x | High |
| Q1 2025 | 4.2x | High |
| Q4 2024 | -0.5x | Net Cash |
CON's net debt is about 3.0 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CON on leverage, with a lower net debt burden relative to earnings.
CON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 88.2 | Overbought |
| Stochastic | 88.4 | Overbought |
CON's weekly RSI is 88 (overbought) and its Stochastic is 88 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CON PE vs Healthcare Sector
| Metric | CON | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 1.6% below |
| PE % | 99 | 54 | 45 pts above |
CON is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over CON on valuation relative to its sector.
CON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $38.9 | 11% above |
| 20 week MA | $35.7 | 21% above |
| 50 week MA | $28.1 | 53% above |
| 100 week MA | $24.6 | 75% above |
OSCR has stronger trend alignment. CON is above 4 of 4 weekly averages versus OSCR above 5 of 5.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
CON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $22.9 | $20.4 | -11% |
| 2025 | $20.4 | $20.0 | -1.8% |
| 2026 YTD | $20.0 | $43.0 | +115% |
CON has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.